SIGLEC1 and colorectal carcinoma: Similarly, the percentages of CD14+CD169+ macrophages in TIMs from the patients with early stage of CRC were significantly lower than that in those with advanced stage of CRC (22.45% vs. 26.93%, P<0.0001, Fig 4A).